


## ICBS Board of Directors

### *Jonathan Baell: Secretary*

Dr Baell is a Principal Research Fellow of the National Health and Medical Research Council, and a Larkins Fellow at Monash University where he is a research-only Professor in Medicinal Chemistry. He is also co-director of the Australian Translational Medicinal Chemistry Facility. He is an Australian National Award-winning medicinal chemist with a battery of medicinal discoveries with 40 granted patents and published in Nature group journals and frequently in Journal of Medicinal Chemistry. His research interests include HTS library design, H2L medchem, infectious and neglected diseases, epigenetic modifiers, and peptidomimetic design and synthesis. He was the principal architect for Australia's 370,000 small molecule HTS library. His 2010 PAINS publication in J. Med. Chem. has already been cited more than 800 times.



URL <https://www.monash.edu/pharm/research/areas/medicinal-chemistry/researchers/jonathan-baell>

1. Major publications (**TOP 5 PUBLICATIONS LAST 5 YEARS**)
2. Russell S...**Baell JB\***, Piggott MJ\*. J. Med. Chem. 59 (2016) 9686-9720. On consecutive covers but too early for high citations, this work showcases medicinal chemistry from HTS hit to a first in class drug candidate with efficacy in vivo against Chagas Disease.
3. **Baell JB\*** & Walters MA. Nature 513 (2014) 481-483. This invited perspective, already with >220 citations, recognizes my leadership in the recognition of compounds that may lead to drug candidates as opposed to those that will waste resource. This research has influenced policy and practise, from journals to Universities to pharmaceutical companies.
4. Dror R et al. Nature **503** (2013) 295-299. Already in the highly cited category (152), we here reveal the structural basis for modulation of a GPCR by allosteric drugs. My original research contribution as medicinal chemist was pivotal in the synthesis of one particularly challenging but key molecule and unique chemotype never before reported, but required to validate the model, with manuscript acceptance a direct consequence.
5. Lessene G et al. Nat. Chem. Biol. 9 (2013) 390-397. Preceded by 3 patents and a licensing deal between WEHI, Abbott and Genentech, and highly cited (125), here we report the medicinal chemistry-led discovery of the globe's only Bcl-XL-specific tool compound. I played a key role in leadership and HTS hit discovery and hit-to-lead medicinal chemistry optimization in directly making breakthrough compounds. This unique tool and potential drug is transforming the landscape of Bcl-XL research.
6. **Baell JB\***. J. Chem. Inf. Mod. 53 (2013) 39-55. Already cited 27 times, here I describe high level chemoinformatics that reveal the limited chemical diversity of HTS libraries and how to design them to be of the highest quality. Global invitations to design HTS libraries in Europe, USA and Canada have followed (50K, 250K and 150K compounds respectively) have followed.